Brief: SynAct Pharma Q2 Sales SEK 0
20/08/2024 06:30
Aug 20 (Reuters) - SynAct Pharma Q2 adjusted EPS SEK -0.47. * Q2 net income SEK -18.628 million * Q2 operating expenses SEK 19.167 million * Q2 cash flow from operating activities SEK -36.153 million
Recent news on SynAct Pharma AB
See all newsSweden's SynAct Pharma Q3 net loss narrows as expenses fall
Brief: SynAct Pharma Q3 Net Income SEK -32.177 Million
Brief: SynAct Pharma Signs First Commercial Partnership For Resomelagon
Brief: WHO Names Resomelagon Among Key Dengue Drug Candidates
Brief: SynAct Pharma Says Advance Analysis Supports Phase 3 Development